Apellis Pharmaceuticals (APLS) News Today $20.34 +0.26 (+1.29%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$19.92 -0.41 (-2.04%) As of 05/2/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Boxer Capital Management LLC Purchases New Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Boxer Capital Management LLC acquired a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,426,000 sharesMay 4 at 6:25 AM | marketbeat.comAQR Capital Management LLC Has $59.24 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)AQR Capital Management LLC grew its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 127.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,856,442 shares of the company's stock after buying an additionaMay 4 at 5:06 AM | marketbeat.comVoya Investment Management LLC Grows Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Voya Investment Management LLC grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 40.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,151 shares of the company's stock after pMay 4 at 4:19 AM | marketbeat.comEnvestnet Asset Management Inc. Lowers Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Envestnet Asset Management Inc. lowered its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 82.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,951 shareMay 4 at 3:14 AM | marketbeat.comEquities Analysts Issue Forecasts for APLS FY2025 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings of ($0.94) pMay 2 at 8:37 AM | marketbeat.comCantor Fitzgerald Initiates Coverage on Apellis Pharmaceuticals (NASDAQ:APLS)Cantor Fitzgerald assumed coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday. They issued an "overweight" rating and a $44.00 price objective on the stock.May 1 at 9:21 AM | marketbeat.comApellis Pharmaceuticals (APLS) to Release Earnings on TuesdayApellis Pharmaceuticals (NASDAQ:APLS) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-apellis-pharmaceuticals-inc-stock/)May 1 at 8:59 AM | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Cantor FitzgeraldMay 1 at 3:01 AM | americanbankingnews.comCantor Fitzgerald Comments on APLS FY2025 EarningsMay 1 at 2:15 AM | americanbankingnews.comApellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial ResultsApril 30, 2025 | globenewswire.comAquatic Capital Management LLC Grows Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Aquatic Capital Management LLC grew its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 5,283.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 129,209 shares of the company'sApril 30, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Cuts Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)T. Rowe Price Investment Management Inc. decreased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 98.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,71April 30, 2025 | marketbeat.comTower Research Capital LLC TRC Has $637,000 Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Tower Research Capital LLC TRC grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 275.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,965 shares of the company's stock after buying an additionApril 30, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Apellis Pharmaceuticals (APLS) with Overweight RecommendationApril 30, 2025 | msn.comIs Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?April 29, 2025 | insidermonkey.comIs Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now?April 29, 2025 | msn.com6APLS : What 9 Analyst Ratings Have To Say About Apellis...April 29, 2025 | benzinga.comMarshall Wace LLP Increases Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Marshall Wace LLP lifted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 292.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 85,495 shares of the company's stock after buying an aApril 29, 2025 | marketbeat.comBarclays PLC Sells 96,332 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Barclays PLC reduced its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 37.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 159,565 shares of the company's stock after selling 96,332 shApril 29, 2025 | marketbeat.comBrokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Price Target at $45.35April 28, 2025 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Hits New 1-Year Low - Here's What HappenedApellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year Low - What's Next?April 27, 2025 | marketbeat.comSyon Capital LLC Takes $621,000 Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Syon Capital LLC acquired a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 19,455 shares of the company's stock, valued at approximately $621,000. Several other hedge funds have also receApril 27, 2025 | marketbeat.comCanada Pension Plan Investment Board Acquires Shares of 35,200 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Canada Pension Plan Investment Board bought a new position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 35,200 shares of the company's stock, valued aApril 27, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Recommendation of "Moderate Buy" by AnalystsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nineteen brokerages that are currently covering the stock, Marketbeat reports. Eight equities research analysts have rated the stock with a hold rating, ten have given aApril 27, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Stock Price Down 4.9% on Analyst DowngradeApellis Pharmaceuticals (NASDAQ:APLS) Trading Down 4.9% on Analyst DowngradeApril 24, 2025 | marketbeat.comIs Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?April 23, 2025 | insidermonkey.comApellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $21.00 by Analysts at Royal Bank of CanadaRoyal Bank of Canada cut their price target on shares of Apellis Pharmaceuticals from $24.00 to $21.00 and set a "sector perform" rating for the company in a report on Monday.April 23, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) is Avoro Capital Advisors LLC's 6th Largest PositionAvoro Capital Advisors LLC raised its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 10.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,222,222 shares of the company'April 23, 2025 | marketbeat.comApellis announces Wheeler to join board of directorsApril 22, 2025 | markets.businessinsider.comApellis price target lowered to $21 from $24 at RBC CapitalApril 21, 2025 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Skye Bioscience (SKYE) and Sarepta Therapeutics (SRPT)April 21, 2025 | markets.businessinsider.comNatixis Buys New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Natixis purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 870,627 shares of the company's stock, valued at approximateApril 21, 2025 | marketbeat.comApellis Announces Craig Wheeler to Join the Board of DirectorsApril 21, 2025 | globenewswire.comApellis price target lowered to $41 from $44 at BofAApril 20, 2025 | markets.businessinsider.comEquities Analysts Offer Predictions for APLS Q1 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at Wedbush cut their Q1 2025 earnings estimates for shares of Apellis Pharmaceuticals in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.46)April 20, 2025 | marketbeat.comRenaissance Technologies LLC Sells 100,418 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Renaissance Technologies LLC lessened its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 27.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 271,913 shares of the company's stock after sApril 20, 2025 | marketbeat.comCerity Partners LLC Boosts Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Cerity Partners LLC boosted its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 48.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,667 shares of the company's stock aftApril 20, 2025 | marketbeat.comResearch Analysts Set Expectations for APLS Q3 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities research analysts at Wedbush issued their Q3 2026 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico expects that the company will post eApril 19, 2025 | marketbeat.comBank of Montreal Can Raises Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Bank of Montreal Can lifted its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 105.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 80,991 shares of the company's stock afApril 19, 2025 | marketbeat.comApellis Pharmaceuticals (APLS) Gets a Buy from Bank of America SecuritiesApril 17, 2025 | markets.businessinsider.comAffinity Asset Advisors LLC Purchases Shares of 50,000 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Affinity Asset Advisors LLC purchased a new position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,000 shares ofApril 17, 2025 | marketbeat.comCapital Fund Management S.A. Decreases Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Capital Fund Management S.A. cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 50.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,433 shares of the company's stock after selling 12April 16, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC grew its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 1.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,838,952 shares of the company's stock after aApril 15, 2025 | marketbeat.comApellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year Low - Time to Sell?Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year Low - Time to Sell?April 9, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 171,909 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Rhenman & Partners Asset Management AB lessened its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 46.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 195,591 shares of the company's stockApril 7, 2025 | marketbeat.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Bought by Landscape Capital Management L.L.C.Landscape Capital Management L.L.C. grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 85.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 49,986 shares of the company's stock after purchasing an additional 23,086April 7, 2025 | marketbeat.comTrexquant Investment LP Takes $6.48 Million Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Trexquant Investment LP purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 203,008 sharesApril 7, 2025 | marketbeat.comNorges Bank Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,086,243 shares of the company's stock, valued at approximately $34,662,000. NorgApril 7, 2025 | marketbeat.comWilliam Blair Has Optimistic Outlook of APLS Q3 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Equities researchers at William Blair raised their Q3 2025 earnings estimates for shares of Apellis Pharmaceuticals in a report issued on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now forecasts that the company will postApril 6, 2025 | marketbeat.comEquities Analysts Issue Forecasts for APLS Q2 EarningsApellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) - Analysts at William Blair boosted their Q2 2026 EPS estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, April 1st. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn $0.20 per shApril 5, 2025 | marketbeat.com Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Media Mentions By Week APLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLS News Sentiment▼0.950.73▲Average Medical News Sentiment APLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLS Articles This Week▼249▲APLS Articles Average Week Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ROIV News RVMD News LNTH News BBIO News TGTX News LEGN News SRPT News TLX News ADMA News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLS) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy APLS Stock Free APLS Stock Alerts